Effect of 20-epi-1α,25-dihydroxyvitamin D3 on the proliferation of human neuroblastoma: Role of cell cycle regulators and the Myc-Id2 pathway

Biochemical Pharmacology

Volumn 65, Issue 12, 2003, Pages 1943-1955

  Gumireddy, Kiranmai ^a,d   Ikegaki, Naohiko ^b   Phillips, Peter C ^b   Sutton, Leslie N ^c   Reddy, C Damodar ^b,c  

^a BROWN UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Myc; Neuroblastoma; p21Cip1; pRB; Retinoic acid receptor ; Vitamin D analog

Indexed keywords

20 EPICALCITRIOL; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BROXURIDINE; CALCITRIOL; CYCLIN D1; PROTEIN P21; RETINOBLASTOMA PROTEIN; RETINOIC ACID RECEPTOR BETA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CLONING; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; EPIMER; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; ONCOGENE C MYB; ONCOGENE C MYC; PRIORITY JOURNAL;

EID: 0037716253     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00205-3     Document Type: Article

References (48)

1. Brodeur G.M., Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. Am. J. Pediatr. Hematol. Oncol. 14:1992;111-116.
2. Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells. J. Natl. Cancer Inst. 68:1982;589-596.
3. Jaffe N. Neuroblastoma: review of the literature and an examination of factors contributing to its enigmatic character. Cancer Treat. Rev. 3:1976;61-82.
4. Maris J.M., Matthay K.K. Molecular biology of neuroblastoma. J. Clin. Oncol. 17:1999;2264-2279.
5. Kushner B.H., Cheung N.K. Neuroblastoma. Pediatr. Ann. 17:1988;269-276.
6. Reynolds C.P., Lemons R.S. Retinoid therapy of childhood cancer. Hematol. Oncol. Clin. North Am. 15:2001;867-910.
7. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP, for the Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-73.
8. Evans T.R., Kaye S.B. Retinoids: present role and future potential. Br. J. Cancer. 80:1999;1-8.
9. Haussler M., Sidell N., Kelly M., Donaldson C., Altman A., Mangelsdorf D. Specific high affinity binding and biologic action of retinoic acid in human neuroblastoma cell lines. Proc. Natl. Acad. Sci. U.S.A. 80:1983;5525-5529.
10. Thiele C.J., Reynolds C.P., Israel M.A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature. 313:1985;404-406.
11. Reynolds C.P., Kane D.J., Einhorn P.A., Matthay K.K., Crouse V.L., Wilbur J.R., Shurin S.B., Seeger R.C. Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog. Clin. Biol. Res. 366:1991;203-211.
12. Bollag W., Peck R. Cancer chemotherapy by combination of retinoids with cytokines and vitamin D analogs. Experimental and clinical results. Ann. Oncol. 5:1994;17-22.
13. 1. Endocrinology. 138:1997;1491-1497.
14. 3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res. 60:2000;2040-2048.
15. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res. 55:1995;2822-2830.
16. 3 receptor-mediating cell cycle arrest and differentiation. J. Nutr. 129:1999;581-586.
17. Schräder M., Bendik I., Becker-André M., Carlberg C. Interaction between retinoic acid and vitamin D signaling pathways. J. Biol. Chem. 268:1993;17830-17836.
18. Carlberg C., Bendik I., Wyss A., Meier E., Sturzenbecker L.J., Grippo J.F., Hunziker W. Two nuclear signaling pathways for vitamin D. Nature. 361:1993;657-660.
19. Ettinger R.A., DeLuca H.F. The vitamin D endocrine system and its therapeutic potential. Adv. Drug Res. 28:1996;269-312.
20. Guyton K.Z., Kensler T.W., Posner G.H. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu. Rev. Pharmacol. Toxicol. 41:2001;421-442.
21. Nishii Y., Okano T. History of the development of new vitamin D analogs: studies on 22-oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy)calcitriol (ED-71). Steroids. 66:2001;137-146.
22. 3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol. 42:1991;1569-1575.
23. 3 analogs and 9-cis-retinoic acid. J. Clin. Invest. 99:1997;349-360.
24. Kip1. Endocrinology. 141:2000;3931-3939.
25. Stio M., Celli A., Treves C. Synergistic antiproliferative effects of vitamin D derivatives and 9-cis-retinoic acid in SH-SY5Y human neuroblastoma cells. J. Steroid Biochem. Mol. Biol. 77:2001;213-222.
26. 3 analogs inhibit growth and induce differentiation in LA-N-5 human neuroblastoma cells. Clin. Exp. Metastasis. 14:1996;239-245.
27. Sivak L.E., Tai K.F., Smith R.S., Dillon P.A., Brodeur G.M., Carroll W.L. Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. Oncogene. 15:1997;1937-1946.
28. Reynolds C.P., Biedler J.L., Spengler B.A., Reynolds D.A., Ross R.A., Frenkel E.P., Smith R.G. Characterization of human neuroblastoma cell lines established before and after therapy. J. Natl. Cancer Inst. 76:1986;375-387.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
30. Grandori C., Cowley S.M., James L.P., Eisenman R.N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16:2000;653-699.
31. Redfern C.P.F., Lovat P.E., Malcolm A.J., Pearson A.D.J. Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9-cis- and all-trans-retinoic acid. Eur. J. Cancer. 31:1995;486-494.
32. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313:1985;1111-1116.
33. Lasorella A., Noseda M., Beyna M., Lavarone A. Id2 is a retinoblastoma protein target and mediates signaling by Myc oncoproteins. Nature. 407:2000;592-598.
34. Lasorella A., Boldrini R., Dominici C., Donfrancesco A., Yokota Y., Inserra A., Iavarone A. Id2 is critical for cellular proliferation and is the oncogenic effector of N-Myc in human neuroblastoma. Cancer Res. 62:2002;301-306.
35. Defacque H., Commes T., Sevilla C., Rochette-Egly C., Marti J. Synergistic differentiation of U937 cells by all-trans-retinoic acid and 1α,25-dihydroxyvitamin D3 is associated with the expression of retinoid X receptor α Biochem. Biophys. Res. Commun. 203:1994;272-280.
36. Qiu H., Zhang W., El-Naggar A.K., Lippman S.M., Lin P., Lotan R., Xu X.C. Loss of retinoic acid receptor-β expression is an early event during esophageal carcinogenesis. Am. J. Pathol. 155:1999;1519-1523.
37. Gebert J.F., Moghal N., Frangioni J.V., Sugarbaker D.J., Neel B.G. High frequency of retinoic acid receptor-β abnormalities in human lung cancer. Oncogene. 6:1991;1859-1868.
38. Swisshelm K., Ryan K., Lee X., Tsou H.C., Peacocke M., Sager R. Down-regulation of retinoic acid receptor-β in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ. 5:1994;133-141.
39. Cheung B., Hocker J.E., Smith S.A., Norris M.D., Haber M., Marshall G.M. Favorable prognostic significance of high-level retinoic acid receptor-β expression in neuroblastoma mediated by effects on cell cycle regulation. Oncogene. 17:1998;751-759.
40. Clagett-Dame M., Verhalen T.J., Biedler J.L., Repa J.J. Identification and characterization of all-trans-retinoic acid receptor transcripts and receptor protein in human neuroblastoma cells. Arch. Biochem. Biophys. 300:1993;684-693.
41. Easton J., Wei T., Lahti J.M., Kidd V.J. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res. 58:1998;2624-2632.
42. 1 phase progression. Genes Dev. 13:1999;1501-1512.
43. 3 and retinoic acid (all-trans and 9-cis) on proliferation, differentiation and programmed cell death in two small cell lung carcinoma cell lines. Biochem. Biophys. Res. Commun. 249:1998;735-744.
44. 3 are associated with enhanced activation of the vitamin D receptor. J. Biol. Chem. 270:1995;10551-10558.
45. Tocchini-Valentini G., Rochel N., Wurtz J.M., Mitschler A., Moras D. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5491-5496.
46. WAF1/CIP1 gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J. Biol. Chem. 271:1996;31723-31728.
47. Wainwright L.J., Lasorella A., Iavarone A. Distinct mechanisms of cell cycle arrest control the decision between differentiation and senescence in human neuroblastoma cells. Proc. Natl. Acad. Sci. U.S.A. 98:2001;9396-9400.
48. Kip1: a key mediator of retinoic acid-induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene. 16:1998;3337-3343.